New hope for Tough-to-Treat lung cancer patients
NCT ID NCT07198217
Summary
This study is testing a specific treatment sequence for people with advanced non-small cell lung cancer who cannot handle standard concurrent chemoradiation. It involves giving chemotherapy first, followed by a shorter, more intense course of radiation, combined with an immunotherapy drug called Tislelizumab. The goal is to see if this approach is effective and safe, providing another option for patients with this serious disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOFRACTIONATED RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zibo Municipal Hospital
RECRUITINGZibo, Shandong, 250000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.